• Mashup Score: 0
    Three decades of progress in nasopharyngeal cancer - 7 month(s) ago

    Tailored management for high-risk locoregional disease, with more effective immunotherapy combinations are key areas

    Source: dailyreporter.esmo.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMO23:After recent advancements in #nasopharingeal #CancerManagement, due to #immunotherapy and an effective #biomarker, what’s next for #NPC? Anthony Chan: treating patients w/ post-treatment residual #EBV DNA is an issue #ESMODailyReporter 👉 https://t.co/xNMCMhmQk6 https://t.co/6u2uzcmCwL

  • Mashup Score: 0
    Comprehensive maturity of nuclear pore complexes regulates zygotic genome activation - 1 year(s) ago

    Experiments in zebrafish indicate that nuclear pore complex (NPC) maturation serves as a molecular timer of zygote genome activation, a key part of the oocyte-to-embryo transition during vertebrate development. Increased size and complexity of NPCs leads to increased nuclear transport of maternal transcription factors, allowing transcription factors to reach thresholds that initiate zygotic…

    Source: Cell
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of westr
      westr

      NICE: Comprehensive maturity of #nuclearpore complexes regulates zygotic genome activation https://t.co/dQfx4l5cSQ #NPC #development #zebrafish #transcriptionfactors #nucleartransport https://t.co/uniGb5DMt4

  • Mashup Score: 0
    What Is Niemann-Pick Disease Type C (NPC)? - 2 year(s) ago

    Dr Marc Patterson, of the Mayo Clinic, explains Niemann-Pick disease type C, a rare lysosomal storage disorder.

    Source: CheckRare
    Categories: Latest Headlines, Rare Disease
    Tweet Tweets with this article
    • Profile photo of CheckRare
      CheckRare

      Marc C. Patterson, MD, at the Mayo Clinic in Rochester, MN, gives an overview of Niemann-Pick disease type C #NPC @MayoClinicHS @MayoClinic @NPCFund @NiemannPickUK @NiemannPickOz @niemann_pick https://t.co/pUjvvvAR8d

  • Mashup Score: 0
    What Is Niemann-Pick Disease Type C (NPC)? - 2 year(s) ago

    Dr Marc Patterson, of the Mayo Clinic, explains Niemann-Pick disease type C, a rare lysosomal storage disorder.

    Source: CheckRare
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CheckRare
      CheckRare

      Marc C. Patterson, MD, at the Mayo Clinic in Rochester, MN, gives an overview of Niemann-Pick disease type C #NPC @MayoClinicHS @MayoClinic @NPCFund @NiemannPickUK @NiemannPickOz @niemann_pick https://t.co/pUjvvvAR8d

  • Mashup Score: 0
    What Is Niemann-Pick Disease Type C (NPC)? - 2 year(s) ago

    Dr Marc Patterson, of the Mayo Clinic, explains Niemann-Pick disease type C, a rare lysosomal storage disorder.

    Source: CheckRare
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CheckRare
      CheckRare

      Marc C. Patterson, MD, at the Mayo Clinic in Rochester, MN, gives an overview of Niemann-Pick disease type C #NPC @MayoClinicHS @MayoClinic @NPCFund @NiemannPickUK @NiemannPickOz @niemann_pick https://t.co/pUjvvvAR8d

  • Mashup Score: 0
    Wolters Kluwer Health - 2 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      The addition of tislelizumab to standard #chemo continues to show improvement in progression-free survival compared with #chemotherapy alone in patients with recurrent/metastatic #nasopharyngealcancer: https://t.co/BupUZYJrSV #NPC https://t.co/xJlMnCdTml

  • Mashup Score: 0
    Wolters Kluwer Health - 2 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      The addition of tislelizumab to standard #chemo continues to show improvement in progression-free survival compared with #chemotherapy alone in patients with recurrent/metastatic #nasopharyngealcancer: https://t.co/BupUZYJrSV #NPC https://t.co/GgSISzDXmc

  • Mashup Score: 2
    Wolters Kluwer Health - 2 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      The addition of tislelizumab to standard #chemo continues to show improvement in progression-free survival compared with #chemotherapy alone in patients with recurrent/metastatic #nasopharyngealcancer: https://t.co/BupUZYJrSV #NPC https://t.co/4PZXA0bnMN

Load More